Logo

Shionogi Presents Results of S-217622 in P-IIb Study for the Treatment of COVID-19 at ECCMID 2022

Share this
Shionogi Presents Results of S-217622 in P-IIb Study for the Treatment of COVID-19 at ECCMID 2022

Shionogi Presents Results of S-217622 in P-IIb Study for the Treatment of COVID-19 at ECCMID 2022

Shots:

  • The P-IIb results from the P-II/III trial evaluating S-217622 (qd for 5 days) vs PBO in 428 patients with COVID-19 across Japan & South Korea
  • S-217622 showed a rapid clearance of SARS-CoV-2 virus, 90% reduction in positive viral titer on Day 4 following 3rd dose, shortened infectious virus shedding by 1-2 day, reduction in viral RNA on days 2, 4, 6 & 9, no difference in a total score of 12 COVID-19 symptoms, improvement in composite score, was well-tolerated with few discontinuations or no serious AEs or death
  • The P-I & IIa part of the P-II/III trial was found to be well-tolerated & cleared SARS-CoV-2. S-217622 is being studied in the P-III study & patients enrollment continues to support regulatory filings in 2022

Ref: Businesswire | Image: Shionogi

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions